The changing face of rheumatoid arthritis: sustained remission for all?
Earlier diagnosis and treatment, plus biological therapies, have transformed the outlook for many patients with rheumatoid arthritis. In the future, new biomarkers for diagnosis, prognosis and therapeutic response will further improve outcomes. Additionally, preclinical diagnosis and tolerogenic therapies could provide sustained remission for some individuals, although ethical and societal challenges must also be addressed before rheumatoid arthritis becomes 'yesterday's disease'.
Isaacs
John D
JD
Institute of Cellular Medicine, Musculoskeletal Research Group, Newcastle University Medical School, Framlington Place, Newcastle-upon-Tyne NE2 4HH, UK. j.d.isaacs@ncl.ac.uk
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis* / Q000188:drug therapy*; D015415:Biomarkers / Q000032:analysis; D042241:Early Diagnosis; D006801:Humans; D011379:Prognosis; D012074:Remission Induction; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D015415:Biomarkers